XORTX Therapeutics Inc (XRTX) Price & Analysis

Compare

31 Followers

XRTX Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$1.15 - C$4.10

Previous CloseN/A

Volume514.00

Average Volume (3M)4.47K

Market Cap

C$5.34M

Enterprise ValueC$3.22M

Total Cash (Recent Filing)$260.02K

Total Debt (Recent Filing)$43.26K

Price to Earnings (P/E)―

Beta1.64

Next Earnings

May 28, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.81

Shares Outstanding3,788,246

10 Day Avg. Volume5,280

30 Day Avg. Volume4,474

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.60

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit10.00T>

Enterprise Value/Ebitda-1.39

Forecast

1Y Price Target

C$19.31

Price Target Upside1269.50% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

---

XORTX Therapeutics Inc News

PremiumThe Fly

Xortx Therapeutics provides update on FDA Type B meeting request

2d ago

XRTX

PremiumThe Fly

Xortx Therapeutics announces grant of European patent

4d ago

XRTX

PremiumThe Fly

Xortx Therapeutics discloses Nasdaq notification regarding minimum bid price

15d ago

XRTX

PremiumCompany Announcements

XORTX Therapeutics Delays Yearly Report Filing

1d ago

XRTX

PremiumCompany Announcements

XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance

2d ago

XRTX

PremiumCompany Announcements

XORTX Secures European Patent for Gout and Kidney Disease Therapies

4d ago

XRTX

PremiumCompany Announcements

XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency

15d ago

XRTX

PremiumCompany Announcements

XORTX Therapeutics Releases Annual Information Form for 2024

1M ago

XRTX

See All TSE:XRTX News

---

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

2.80% Insiders

―

Mutual Funds

7.00% Other Institutional Investors

90.20% Public Companies and

Individual Investors

Detailed Ownership Overview >

XRTX FAQ

What was XORTX Therapeutics Inc’s price range in the past 12 months?

XORTX Therapeutics Inc lowest stock price was C$1.15 and its highest was C$4.10 in the past 12 months.

What is XORTX Therapeutics Inc’s market cap?

XORTX Therapeutics Inc’s market cap is C$5.34M.

When is XORTX Therapeutics Inc’s upcoming earnings report date?

XORTX Therapeutics Inc’s upcoming earnings report date is May 28, 2025 which is in 26 days.

How were XORTX Therapeutics Inc’s earnings last quarter?

Currently, no data Available

Is XORTX Therapeutics Inc overvalued?

According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does XORTX Therapeutics Inc pay dividends?

XORTX Therapeutics Inc does not currently pay dividends.

What is XORTX Therapeutics Inc’s EPS estimate?

XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does XORTX Therapeutics Inc have?

XORTX Therapeutics Inc has 3,788,246 shares outstanding.

What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of XORTX Therapeutics Inc?

Currently, no hedge funds are holding shares in TSE:XRTX

---

Company Description

XORTX Therapeutics Inc

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

---

XRTX Stock 12 Month Forecast

Average Price Target

C$19.31

▲(1269.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","15":"C$15","30":"C$30","45":"C$45","60":"C$60"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19.31151684,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$19.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$19.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.31151684,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$19.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,15,30,45,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2021","6":"Jan<br/>2022","9":"Apr<br/>2022","12":"Feb<br/>2025","25":"Feb<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,2.759347449230769,4.138694898461539,5.518042347692308,6.897389796923077,8.276737246153846,9.656084695384617,11.035432144615385,12.414779593846156,13.794127043076923,15.173474492307694,16.55282194153846,17.932169390769232,{"y":19.31151684,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,2.7592307692307694,4.138461538461538,5.5176923076923075,6.896923076923077,8.276153846153846,9.655384615384616,11.034615384615385,12.413846153846155,13.793076923076924,15.172307692307694,16.551538461538463,17.93076923076923,{"y":19.31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,2.759347449230769,4.138694898461539,5.518042347692308,6.897389796923077,8.276737246153846,9.656084695384617,11.035432144615385,12.414779593846156,13.794127043076923,15.173474492307694,16.55282194153846,17.932169390769232,{"y":19.31151684,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.96,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.02,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":54.94,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":59.22,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.24,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.65,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.5,"date":1640995200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.89,"date":1643673600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.65,"date":1646092800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.51,"date":1648771200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.51,"date":1648771200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >